Moderna (MRNA) Cost of Revenue (2020 - 2026)

Moderna (MRNA) has reported Cost of Revenue for 7 consecutive years, with $93.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 21.85% year-over-year to $93.0 million in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 16.76% increase from a year earlier, with the FY2025 full-year figure at $868.0 million, down 40.71% from the prior year.
• Cost of Revenue was $93.0 million for Q2 2026 at Moderna, down from $955.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.2 billion in Q3 2023 and troughed at $90.0 million in Q1 2025.
• A 5-year average of $665.1 million and a median of $622.5 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue plunged 87.88% in 2024 and surged 961.11% in 2026, its largest moves.
• Over 5 years, Cost of Revenue stood at $400.0 million in 2022, then surged by 132.25% to $929.0 million in 2023, then decreased by 20.45% to $739.0 million in 2024, then slumped by 38.84% to $452.0 million in 2025, then tumbled by 79.42% to $93.0 million in 2026.
• The last three Cost of Revenue figures came in at $93.0 million (Q2 2026), $955.0 million (Q1 2026), and $452.0 million (Q4 2025), per Business Quant data.